http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9636427-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8f3fc0bcee25a1161415431ccb1faf7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-108 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2016-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9601050ba5766deaabe51083a8abcc9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_668e8a2d8d56c8e0abc2141542bf898f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a09c23ea1623ed803daabdd5a321950 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02f9be74703a2dc7948685308b9a0407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_688a8bd8aeff233f2888b88cbf320b05 |
| publicationDate | 2017-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-9636427-B2 |
| titleOfInvention | Process for preparing a pharmaceutical formulation of contrast agents |
| abstract | The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being chosen from DOTA, NOTA, DOTAGA, DO3A, BT-DO3A, HP-DO3A and PCTA, and is preferably DOTA, the said process comprising the following successive steps: b) preparation of a liquid pharmaceutical composition containing, firstly, the complex of macrocyclic chelate with a lanthanide, and, secondly, free macrocyclic chelate and/or free lanthanide; c) measurement in the pharmaceutical formulation obtained in step b) of the concentration of free macrocyclic chelate C ch1 and/or of free lanthanide C lan1 ; d) adjustment of C ch1 and/or of C lan1 so as to obtain C ch1 =C t ch1 and C lan1 =0, wherein C t ch1 is the target concentration of free macrocyclic chelate in the final liquid pharmaceutical formulation. |
| priorityDate | 2008-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 117.